Recommendation of the President – Remsima (infliximab)

On 28 February 2025, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 24/2025 on the appraisal of Remsima (infliximab) as part of the B.35. drug program “Treatment of patients with psoriatic arthritis (PsA) (ICD-10: L40.5, M07.1, M07.2, M07.3)”

Publication in Public Information Bulletin (BIP) >>